Other Clinical Trial - Improving the Assessment of Hypersomnolence

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The overall purpose of this study is to employ a pragmatic, multidimensional assessment of hypersomnolence that "piggybacks" on routine clinical care in patients with suspected disorders of central nervous system (CNS) hypersomnia, to determine whether these additional objective and subjective assessments are useful in the diagnosis and management of these patients.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00477009` - Effects From a Mandibular Repositioning Appliance in Patients With Obstructive Sleep Apnea and Snoring	N/A
	Completed	`NCT01554527` - Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children	N/A

NCT number	NCT02884505
Study type	Observational
Source	University of Wisconsin, Madison
Contact
Status	Completed
Phase
Start date	August 25, 2017
Completion date	June 30, 2019

Improving the Assessment of Hypersomnolence

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms